hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06339138, orgStudyIdInfo id: 17-010944, secondaryIdInfos id: NCI-2024-00971, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), secondaryIdInfos id: 17-010944, type: OTHER, domain: Mayo Clinic in Rochester, briefTitle: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2018-02-20, primaryCompletionDateStruct date: 2027-01-31, completionDateStruct date: 2027-01-31, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors., conditionsModule conditions: Chromophobe Renal Cell Carcinoma, conditions: Clear Cell Papillary Renal Tumor, conditions: Clear Cell Renal Cell Carcinoma, conditions: Kidney Oncocytoma, conditions: Papillary Renal Cell Carcinoma, conditions: Urothelial Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 874, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Identify novel methylated DNA markers in tissue for malignant renal and urothelial tumors, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, status: RECRUITING, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Clinical Trials Referral Office, role: CONTACT, phone: 855-776-0015, email: mayocliniccancerstudies@mayo.edu, contacts name: John C. Cheville, M.D., role: PRINCIPAL_INVESTIGATOR, contacts name: John B. Kisiel, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06339125, orgStudyIdInfo id: 2023p003637, briefTitle: Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: Crico, collaborators name: Inspiren Inc, collaborators name: RGI Informatics LLC, descriptionModule briefSummary: Annually, in the United States there are 700,000 - 1,000,000 inpatient falls reported, and one-third of patients sustain an injury. The average estimated cost per fall is $6,694, resulting in over $1.4 -1.9 billion dollars in losses each year (AHRQ, 2017). This study aims to compare the impact of different fall prevention strategies on the rate of occurrence of falls and falls with injury in an academic medical center on three adult medical units. While maintaining the usual standard of care for fall prevention, each unit will add one of the following: (1) use of a fall risk alert to nurses using an algorithm based on electronic health record data or (2) computerized camera visualization or (3) a combination of both., conditionsModule conditions: Falls and Falls With Injury, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: An observational cohort, mixed-methods study design will be conducted to determine the impact and effectiveness of usual care and three different fall prevention strategies that exceed the standard of care on three inpatient units at MGH over one year. Unit 1 will employ streaming analytics and the MGH algorithm only, Unit 2 will employee Inspiren's AUGI computer visualization only and Unit 3 will employ the combined streaming analytic/MGH algorithm and Inspiren's AUGI device. Unit 4, the control unit, will serve as an internal comparison group from the same institution. In addition to the study interventions all four units will continue to maintain usual MGH evidence-based practice, standards of care for fall prevention., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 4500, type: ESTIMATED, armsInterventionsModule interventions name: Fall prevention algorithm, interventions name: Inspiren camera visualization, outcomesModule primaryOutcomes measure: Falls, primaryOutcomes measure: Falls with injury, secondaryOutcomes measure: Nurse perceptions, secondaryOutcomes measure: Nurse perceptions, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339112, orgStudyIdInfo id: 2024/10, briefTitle: The Effect of Playing With a Toy Nebulizer and Watching Cartoons on the Fear and Anxiety on Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Tarsus University, class: OTHER, descriptionModule briefSummary: This research was planned as a randomized controlled experimental type to determine the effect of playing with a toy nebulizer and watching cartoons on children's fear and physiological parameters in 3-6 year old children who were administered inhaler medication. The population of the study, planned as a randomized controlled experimental study, will consist of 4-6 year old children who apply to Tarsus State Hospital pediatric services and receive inhaler treatment. According to the power analysis performed for the sample size, the power of the sample was calculated with the G\*Power 3.1 program, in line with the literature (Durak 2019; Özsamuri 2020). While the amount of Type I error was 0.05 and the power of the test was 0.95 (α= 0.05, 1-β= 0.95), the minimal sample size was calculated as 105 children (35 children in each group). Considering the possible losses from the sample for any reason during the study period, it was planned to increase the number of samples by 10% and include 38 children in the study and control groups. Child Information Form, Fear Assessment Scale and Child Anxiety Scale-State Scale will be used to collect data., conditionsModule conditions: Fear, conditions: Anxiety, conditions: Inhalant Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomized controlled experimental study, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 114, type: ESTIMATED, armsInterventionsModule interventions name: Playing with toy nebulizer, interventions name: Cartoon, outcomesModule primaryOutcomes measure: fear, primaryOutcomes measure: anxiety, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 6 Years, stdAges: CHILD, contactsLocationsModule locations facility: Tarsus State Hospital, city: Mersin, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06339099, orgStudyIdInfo id: P.T.REC/012/002489, briefTitle: Loaded Gait Training on Gross Motor Function in Cerebral Palsy, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-02-26, primaryCompletionDateStruct date: 2023-10-15, completionDateStruct date: 2024-03-15, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: A randomized controlled trial aimed to evaluate the additional effect loaded gait training to conventional physical therapy program on gross motor function and the knee extensors strength in children with bilateral spastic cerebral palsy. Children were divided randomly into two equal groups. The control group received a conventional physical therapy program, while the intervention group received the same program plus loaded gait training. Gross motor functions and knee extensor strength were measured., conditionsModule conditions: Cerebral Palsy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Children were randomly assigned into two equal groups., primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double blinding. Parents were also blinded., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ACTUAL, armsInterventionsModule interventions name: Conventional physical therapy program, interventions name: Loaded gait training, outcomesModule primaryOutcomes measure: Gross motor function, primaryOutcomes measure: knee extensor strength, eligibilityModule sex: ALL, minimumAge: 5 Years, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule locations facility: Faculty of Physical Therapy, Cairo University, city: Giza, state: Cairo, zip: 12613, country: Egypt, geoPoint lat: 30.00808, lon: 31.21093, hasResults: False
protocolSection identificationModule nctId: NCT06339086, orgStudyIdInfo id: BPR-201-I-III-01, briefTitle: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-08-30, completionDateStruct date: 2025-12-30, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Chengdu Brilliant Pharmaceutical Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous injection) as add-on to metformin for 32 weeks.Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar., conditionsModule conditions: Type 2 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 478, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide Injection, interventions name: Semaglutide Injection(Ozempic®), interventions name: Metformin, outcomesModule primaryOutcomes measure: Change in HbA1c, secondaryOutcomes measure: Change in HbA1c, secondaryOutcomes measure: Change in FPG, secondaryOutcomes measure: Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5%, secondaryOutcomes measure: Proportion of participants who achieved HbA1c<7.0%，HbA1c≤6.5% with no hypoglycemic event, secondaryOutcomes measure: Change in Body Weight, secondaryOutcomes measure: Proportion of participants with Weight Loss≥5%, ≥10% and ≥15%, secondaryOutcomes measure: Change in Diastolic and Systolic Blood Pressure, secondaryOutcomes measure: Changes in Blood Lipids, secondaryOutcomes measure: Incidence and severity of Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339073, orgStudyIdInfo id: 2021NZKY-045-01, briefTitle: CT-based Model for Predicting Prolonged Weaning in Patients With Abdominal Trauma, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2023-12-15, completionDateStruct date: 2024-02-05, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Jinling Hospital, China, class: OTHER, descriptionModule briefSummary: Critically ill patients often require tracheal intubation for mechanical ventilation, and timely weaning is crucial for airway management and reducing complications. However, there is currently a lack of an effective tool to predict weaning time in critically ill patients. This retrospective study established an effective nomogram model for predicting the time of weaning from mechanical ventilation in abdominal trauma patients by considering multiple perspectives. The model has been validated and demonstrated good performance in terms of discrimination, calibration, and clinical utility. Moreover, the model can effectively predict the prognosis of critically ill patients. The findings of this study have important implications for guiding respiratory management in clinically critically ill patients, particularly trauma patients., conditionsModule conditions: Wounds and Injuries, conditions: Ventilation Therapy; Complications, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 1023, type: ACTUAL, armsInterventionsModule interventions name: mechanical ventilation, outcomesModule primaryOutcomes measure: Prolonged mechanical ventilation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: the General Surgical Department of Jinling Hospital, city: Nanjing, state: Jiangsu, zip: 210002, country: China, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06339060, orgStudyIdInfo id: RTS-022, briefTitle: An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3)., acronym: PALACE3, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2028-03-01, completionDateStruct date: 2028-03-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Ruijin Hospital, class: OTHER, descriptionModule briefSummary: Patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group).The 3-year overall survival rate is the primary outcome., conditionsModule conditions: Esophageal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, maskingDescription: Randomize patients who meet the inclusion criteria Grouping, randomly assigned to the experimental group in a 1:1 ratio (organ preservation strategy after neoadjuvant chemotherapy combined with immunotherapy) And the control group (limited time for esophageal cancer radical surgery after neoadjuvant radiotherapy and chemotherapy), enrollmentInfo count: 356, type: ESTIMATED, armsInterventionsModule interventions name: Experimental: Arm 1 Organ preservation, interventions name: Active Comparator: Arm 2 Surgery, outcomesModule primaryOutcomes measure: 3-year overall survival rate, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06339047, orgStudyIdInfo id: 2024/09, briefTitle: The Effect of Projector Kaleidoscope and Cartoons on Anxiety, Fear, and Pain in Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Tarsus University, class: OTHER, descriptionModule briefSummary: The research will be conducted with children hospitalized in Tarsus State Hospital Children's Clinics and who meet the sampling criteria.The population of the study, which is planned as a randomized controlled experimental study, will consist of children aged 4-10 years old who are admitted to the pediatric surgery service of Tarsus State Hospital and will undergo outpatient surgical intervention.In collecting research data; the Introductory Information Form, Child Anxiety Scale, Child Fear Scale, Wong-Baker Pain Scale and Vital Signs Follow-up Form will be used., conditionsModule conditions: Anxiety and Fear, conditions: Pain, conditions: Surgery, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomized controlled experimental study, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule interventions name: Projector Kaleidoscope, interventions name: Cartoon, outcomesModule primaryOutcomes measure: Anxiety, primaryOutcomes measure: Fear, primaryOutcomes measure: Pain after surgery, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Tarsus State Hospital, city: Mersin, country: Turkey, geoPoint lat: 36.79526, lon: 34.61792, hasResults: False
protocolSection identificationModule nctId: NCT06339034, orgStudyIdInfo id: STUDY, briefTitle: Repurposing Lithium for Parkinson's Disease: a RCT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-10, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: State University of New York at Buffalo, class: OTHER, collaborators name: The Cure Parkinson's Trust, descriptionModule briefSummary: This study will examine the effects of lithium 20mg/day compared to placebo on MRI and blood-based biomarkers among 20 early-stage Parkinson's disease patients., conditionsModule conditions: Parkinson Disease, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Double-blind, placebo-controlled, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Lithium, interventions name: Placebo, outcomesModule primaryOutcomes measure: MRI-derived free water (FW) levels., primaryOutcomes measure: Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression, primaryOutcomes measure: Serum neurofilament light chain (NfL), secondaryOutcomes measure: PBMC superoxide dismutase type-1 (SOD-1) mRNA expression, secondaryOutcomes measure: PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio, secondaryOutcomes measure: PBMC pThr308 and pS473/total protein kinase B (Akt) ratios, secondaryOutcomes measure: Serum interleukin-6, secondaryOutcomes measure: Serum glial fibrillary acidic protein (GFAP), secondaryOutcomes measure: Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination), secondaryOutcomes measure: Montreal Cognitive Assessment (MoCA), secondaryOutcomes measure: Parkinson's Anxiety Scale, secondaryOutcomes measure: Geriatric Depression Scale-15, secondaryOutcomes measure: Fatigue Severity Scale, secondaryOutcomes measure: Insomnia Severity Index, secondaryOutcomes measure: Parkinson's Disease Questionnaire-8, secondaryOutcomes measure: Levodopa equivalent daily dose (LEDD), otherOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UBMD Neurology, city: Williamsville, state: New York, zip: 14221, country: United States, contacts name: Thomas Guttuso, MD, role: CONTACT, phone: 716-932-6080, email: tguttuso@buffalo.edu, contacts name: Amelia Cheney, role: CONTACT, email: acheney4@buffalo.edu, contacts name: Thomas Guttuso, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.96395, lon: -78.73781, hasResults: False
protocolSection identificationModule nctId: NCT06339021, orgStudyIdInfo id: DAPT-OCT, briefTitle: OCT or Angiography Guided De-escalation of DAPT, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2026-12-01, studyFirstPostDateStruct date: 2024-04-01, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: Shenyang Northern Hospital, class: OTHER, descriptionModule briefSummary: Optical coherence tomography (OCT) offers a high-resolution intravascular imaging modality to accurately assess vessel and lumen geometry and identify the hallmark of a culprit lesion including plaque disruption and thrombus. In addition, the incorporation of the MLD MAX algorithm into daily practice guides an efficient and easily-memorable workflow for optimized OCT-guided percutaneous coronary intervention (PCI) with drug-eluting stents (DES). Regarding the antithrombotic therapy after revascularization, the 2023 ESC guidelines recommend the P2Y12 receptor inhibitor de-escalation (i.e. switching from ticagrelor to clopidogrel) in ACS patients may be considered as an alternative strategy to the default treatment regimen in order to reduce the risk of bleeding events.Based on the above conclusions, we designed a single-center, prospective, randomized controlled, exploratory study trial to evaluate whether the utility of OCT for guiding PCI with DES followed by antiplatelet de-escalation therapy could further reduce the stent-induced intimal hyperplasia of STEMI patients after stent implantation., conditionsModule conditions: Optical Coherence Tomography, conditions: Dual Antiplatelet Therapy, conditions: Antiplatelet De-escalation, conditions: Neointimal Coverage, conditions: ST Elevation Myocardial Infarction, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: OCT-guided PCI, interventions name: Conventional angiography-based PCI, interventions name: DAPT de-escalation, interventions name: default DAPT regimen, outcomesModule primaryOutcomes measure: Neointimal thickness after DES implantation, secondaryOutcomes measure: Major adverse cardiovascular and cerebrovascular events (MACCE), secondaryOutcomes measure: BARC types 2-5 bleeding, secondaryOutcomes measure: In-stent thrombosis, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Northern Hospital, city: Shenyang, state: Liaoning, country: China, contacts name: Yaling Han, Dr, role: CONTACT, phone: +86-24-28897313, email: cardiology@163.com, contacts name: Yaling Han, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Yang Li, MD, role: SUB_INVESTIGATOR, contacts name: Yi Li, MD, role: SUB_INVESTIGATOR, geoPoint lat: 41.79222, lon: 123.43278, hasResults: False